Stock 4593 HEALIOS K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Healios K.K.

Equities

4593

JP3835100003

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
194 JPY -0.51% Intraday chart for Healios K.K. +2.11% +17.58%
06-20 Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute MT
06-19 Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Healios K.K.

Healios to Book $3 Million Upfront Payment as Sales Revenue in Q2 Following License Deal with Astellas Institute MT
Healios K.K. Enters into License Agreement with Astellas Institute for Regenerative Medicine CI
Healios Enters Alliance, Bond Purchase Deal with Alfresa MT
Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen MT
Healios K.K. Enters into Joint Research Agreement with AND Medical Group CI
Healios Concludes Purchase of Athersys Assets, Becoming Sole Owner of MultiStem IP MT
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC . CI
Japanese Shares Hit Fresh 52-Week Peak Ahead of Inflation Data MT
Healios Proposes Reduction of Capital Stock, Reserves, Surplus Appropriation MT
Jefferies Adjusts Healios K.K.’s Price Target at 140 Yen From 170 Yen, Keeps at Hold MT
Healios K.K. announced that it has received ¥2.2600715 billion in funding CI
Healios K.K. and ProcellCure Inc. Announce Start of ARDS Clinical Trial in Japan CI
Healios K.K. announced that it expects to receive ¥2.2600715 billion in funding CI
Healios and ProcellCure Initiate Clinical Trial for ARDS Treatment MT
Japanese Shares Finish Lower After Key Economic Data MT
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan CI
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal MT
Healios Secures LOI on Joint Research with AND MT
Healios K.K. AND Medical Group Enter into A Letter of Intent for A Basic Agreement for Joint Research CI
Healios Steps In as Primary Bidder and Lender for Athersys’s Asset Sale Amidst Bankruptcy MT
Healios K.K. entered into an asset purchase agreement to acquire Substantially all assets of ABT Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC for $2.8 million. CI
Healios, Nobelpharma in Talks for Stem Cell Therapy Alliance for ARDS MT
Healios Invests in Arktus Therapeutics at Undisclosed Amount MT
Healios K.K. (TSE : 4593) agreed to acquire an unknown minority stake in Arktus Therapeutics Co., Ltd. CI
California Institute for Regenerative Medicine Awards $1 Million from the California Institute for Regenerative Medicine for Healios' Hypo-immune UDC CI

Chart Healios K.K.

Chart Healios K.K.
More charts

Company Profile

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.
Sector
Biotechnology & Medical Research
Calendar
2024-08-07 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Healios K.K.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
195 JPY
Average target price
280 JPY
Spread / Average Target
+43.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
HEALIOS K.K. Stock Healios K.K.
+17.58% 109M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 115B
ARGENX SE Stock argenx SE
+22.18% 26.64B
BIONTECH SE Stock BioNTech SE
-21.81% 19.91B
GENMAB A/S Stock Genmab A/S
-16.77% 16.32B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.49B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.52B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.83B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4593 Stock
  4. News Healios K.K.
  5. Healios Proposes Reduction of Capital Stock, Reserves, Surplus Appropriation